Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104241 | 0.83 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1PKM | |
| SCHEMBL23589878 | 0.81 | GAA (0.43) | GAAKMT2AMEN1TP53SMN1; SMN2 | |
| SCHEMBL22014139 | 0.79 | MEN1 (0.38) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL23475971 | 0.79 | KMT2A (0.42) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL14049277 | 0.78 | MEN1 (0.67) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL10088093 | 0.78 | SMN1; SMN2 (0.59) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL19161331 | 0.78 | KMT2A (0.43) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL19069757 | 0.78 | CASP2 (0.50) | KMT2AMEN1HPGDCNR1 | |
| SCHEMBL16248615 | 0.78 | ALDH1A1 (0.57) | KMT2AMEN1TP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL23710898 | 0.78 | KMT2A (0.46) | GAAKMT2AMEN1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | GAA 1336/4885KMT2A 926/4885MEN1 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.